This article is more than 5 years old. Information may no longer be current.
Interventional Spine announces FDA clearance of Lordotic Opticage
Click Here to Manage Email Alerts
Interventional Spine Inc. has received clearance from the FDA for its 8° Lumbar Lordotic Opticage Expandable Intervertebral Body Fusion Device, which is a lumbar intervertebral body fusion device designed for use with autogenous bone graft in patients with degenerative disc disease.
The device joins the other Interventional Spine Opticage Expandable Interbody Fusion Devices cleared by the FDA last year. The Lordotic Opticage also uses the company’s PerX360 System, according to a company press release.
Surgeons can use the device to help correct the pressure on the lower spine and potentially ease the lumbar lordotic pain patients may experience.
The new Opticage can be implanted through a posterior, transforaminal or lateral approach and provides optimum graft injection through its patented delivery system, according to the release.
“Based on existing market trends, Interventional Spine expects the new Lordotic Opticages to be a significant source of revenue for the company,” Joseph Darling, chief operating officer of Interventional Spine, said in the press release. “We are very excited with the latest addition of the Lordotic 8° Opticage, as it provides a pathway for Interventional Spine’s vision of becoming a leader in the expandable cage market, and addresses the needs of surgeons and patients worldwide.”
Reference: